---
schema_version: "secwatch.filing_event.v1"
accession: "0000886744-25-000068"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:29:29.331828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Geron Q3 2025 RYTELO revenue $47.2M; net loss narrows to $18.4M; FY25 opex guidance lowered

## Summary
- RYTELO net product revenue $47.2M in Q3 2025 (vs $28.2M in Q3 2024); demand down 3% QoQ.
- Net loss $18.4M ($0.03/share) compared to $26.4M ($0.04/share) in Q3 2024.
- Completed enrollment of 320 patients in Phase 3 IMpactMF trial for imetelstat in myelofibrosis.
- FY 2025 operating expense guidance reduced to $250M-260M from prior $270M-285M.
- Appointed Ahmed ElNawawi as EVP, Chief Commercial Officer; three other executives added.

## SEC filing metadata
- accession: 0000886744-25-000068
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/0000886744-25-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886744-25-000068
- JSON: https://secwatch.observer/filing/0000886744-25-000068.json
- Plain text: https://secwatch.observer/filing/0000886744-25-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.